ArticleArthritis & rheumatology (Hoboken, N.J.)2026
Per- and Polyfluoroalkyl Substances and Knee Osteoarthritis: Data From the Osteoarthritis Initiative.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveTo examine whether concentrations of specific per- and polyfluoroalkyl substances (PFAS) and a mixture of PFAS relate to incident knee osteoarthritis (KOA) and knee pain progression.
methodsAmong a case-cohort sample from the OA Initiative (n = 1,878), we examined associations of serum concentrations of eight PFAS with odds of developing over the subsequent 48 months (1) symptomatic KOA and (2) a clinically meaningful change in the Western Ontario and McMaster Universities OA Index knee pain score. We used weighted logistic regression to assess single PFAS (continuous and quartiles) and quantile g-computation to assess the PFAS mixture in relation to our outcomes, accounting for sociodemographics.
resultsFifty-eight percent of participants were female with a mean age of 62 years and body mass index of 28.6 kg/m
conclusionIn a large cohort at risk for KOA, higher perfluorooctanoic acid and PFNA serum concentrations may be associated with a greater likelihood of symptomatic KOA incidence and knee pain progression.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.